MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a international leader in specialized, investigation-driven pharmaceutical-top quality cannabis extraction, distillation and derivative goods, now announced it will provide cannabis concentrate goods in Denmark to two new health-related cannabis shoppers below two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ 1st provide agreements for the export of completed goods to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal goods two years ago as element of a 4-year pilot system. The system supplies individuals with protected item access and national overall health authorities with patient information that they can use to have an understanding of usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mostly ladies among the ages of 42-64) received cannabis-primarily based medicinal goods from 429 prescribing physicians below this system in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the international cannabis market place for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related market place with new and revolutionary health-related cannabis focused goods positions us for added development in Europe and adds to MediPharm Labs all-significant physique of know-how that we are leveraging to boost the design and style of our formulations for individuals and shoppers everywhere.”
Below the agreements, 1 which has an initial two-year term and the second a 1-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil goods that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its shoppers to commence in October 2020, pending regulatory approval by applicable overall health authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured numerous pretty eye-catching domestic and international provide agreements with higher top quality partners, now which includes new shoppers in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new business enterprise wins are a clear and significant validation of our choice to make a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production below all of these agreements.”
MediPharm Labs Australia received its Superior Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May possibly 2020, which enables it to sell cannabis APIs and completed goods to nations across the EU, which includes Denmark. The Organization entered into its 1st European white-label cannabis provide agreement that exact same month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Marketplace
Denmark launched its 4-year health-related cannabis pilot system on January 1st, 20181. Post-harvest Superior Manufacturing Processes (GMP) is expected for distribution of health-related cannabis goods in Denmarktwo.
By means of the system, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 regions: discomfort brought on by a number of sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy remedy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an comprehensive critique of literature as effectively as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical top quality cannabis oil and concentrates and sophisticated derivative goods using a Superior Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an specialist, investigation-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 key extraction lines for delivery of pure, trusted and precision -dosed cannabis goods for its shoppers. By means of its wholesale and white label platforms, they formulate, customer-test, method, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a international leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure
Supply: https://www.financialbuzz.com/breaking-news-medipharm-labs-enters-denmark-health-related-cannabis-market place-secures-new-white-label-provide-shoppers/